These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27960586)

  • 1. Long-Term Outcomes in Patients with Neovascular Age-Related Macular Degeneration Who Maintain Dry Macula after Three Monthly Ranibizumab Injections.
    Kim KM; Kim JH; Chang YS; Kim JW; Kim CG
    Semin Ophthalmol; 2018; 33(3):371-376. PubMed ID: 27960586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term changes in retinal layers in patients undergoing intravitreal ranibizumab for neovascular age-related macular degeneration : Retinal layers after anti-VEGF therapy.
    Inan ÜÜ; Baysal Z; Inan S
    Int Ophthalmol; 2019 Dec; 39(12):2721-2730. PubMed ID: 31069616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
    Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
    BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration.
    Shin HJ; Chung H; Kim HC
    Retina; 2013 May; 33(5):964-70. PubMed ID: 23348865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
    Mathew R; Richardson M; Sivaprasad S
    Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period.
    Wickremasinghe SS; Xie J; Guymer RH; Wong TY; Kawasaki R; Qureshi S
    Eye (Lond); 2012 Jul; 26(7):958-66. PubMed ID: 22562186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration.
    Kang HM; Lee SJ; Kim CG; Chung EJ; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results.
    Nishimura T; Machida S
    Jpn J Ophthalmol; 2019 Jan; 63(1):90-99. PubMed ID: 30470956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.
    Feltgen N; Bertelmann T; Bretag M; Pfeiffer S; Hilgers R; Callizo J; Goldammer L; Bemme S; Hoerauf H
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):923-934. PubMed ID: 28102456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
    Kim JH; Lee TG; Chang YS; Kim CG; Cho SW
    Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration.
    Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB
    Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs.
    Frennesson CI; Nilsson SE
    Acta Ophthalmol; 2014 May; 92(3):216-20. PubMed ID: 23452436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
    Valverde-Megías A; Veganzones-de-Castro S; Donate-López J; Maestro-de-Las-Casas ML; Megías-Fresno A; García-Feijoo J
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2091-2098. PubMed ID: 28744656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.